International Stem Cell Corp. (ISCO): Strong 2013 Achievements, Financial Results Foster Optimism in 2014
International Stem Cell, a biotech company developing novel stem cell-based therapies and biomedical products, in conference call yesterday detailed its financial results and clinical achievements in the 12 months ended December 31, 2013, and offered insight into upcoming 2014 events. “So, 2013 was a very good year for International Stem Cell Corporation,” Dr. Simon Craw, executive vice president of ISCO stated in the conference call. “We continue to execute on our business plans, growing revenues to over $6 million while containing costs, but also importantly achieving a number of R&D milestones that position us extremely well for 2014 and beyond.”…